Secondary Navigation Menu

Audience Switcher Modal

Country and Audience Choose Modal

Created and funded​ 
by Bayer.

ESC HF 2026
Medical Information
ESC 2026
Medical Information

 

    Home

    Commited to a healthier life​

    for people with cardiovascular disease

    Acoramidis

    ACORAMIDIS​

    Acoramidis Clinical Trial Programme​
    Access the PDF
    EU SmPC Acoramidis
    Access the PDF
    Finerenone

    FINERENONE

    Finerenone Information Kit
    Access the PDF
    How does Finerenone differ from steroidal MRAs?
    Access the PDF
    Heart Failure Case Series: Clinical Decision-Making in Practice
    Show Webpage
    EMA prescribing information for Finerenone
    Access the PDF
    Heart & Kidney Care Alliance
    Show Webpage
    Vericiguat​

    VERICIGUAT​

    MDT VICTOR results
    Access the PDF
    MDT VICTOR and VICTORIA pooled analysis
    Access the PDF
    MDT Effect of vericiguat on wHF in a contemporary HFrEF population
    Access the PDF
    MDT Safety and tolerability of vericiguat in the contemporary era of GDMT
    Access the PDF
    Vericiguat Reactive Deck
    Access the PDF
    Vericiguat MoA animated infographic
    Access the Video
    Unmet needs animated infographic
    Access the Video
    Totality of evidence animated infographic
    Access the Video
    VICTOR baseline characteristics animated infographic
    Access the Video
    VICTOR Results animated infographic
    Access the Video
    AskBio​

    AskBio​

    Askbio podium deck
    Access the PDF

     

    MA-M_ACR-ES-0155-1 / April 2026

    Report a side effect:
    For adverse event reporting, please contact the Spanish system for Pharmacovigilance of human use medicines, www.notificaram.es. For other regions, please refer to your pharmacovigilance local authority. 

    Para notificar una reacción adversa, por favor, contacte con el sistema español de Farmacovigilancia de medicamentos de uso humanos, www.notificaram.es. Para otras regiones, por favor consulte su autoridad local de farmacovogilancia.

    This website is to be presented at the Annual Congress of the of the ESC HF, Saturday, 9 May - Tuesday, 12 May 2026, Barcelona - Spain. Product labels may vary from country to country, please refer to your local Prescribing Information for the proper usage and indications approved in your market.


    Finerenone in Spain is indicated in adults for the treatment of CKD (with albuminuria) associated with type 2 diabetes. The indication “Treatment of symptomatic chronic HF EF ≥40%” is approved in Spain. However, the pricing and reimbursement process is ongoing. Kerendia 40 mg is currently not marketed in Spain. 

    Finerenona en España está indicada en adultospara el tratamiento de la ERC (con albuminuria) asociada a diabetes tipo 2. La indicación “Tratamiento de la IC crónica sintomática FE ≥40%” está autorizada en España. Sin embargo, el proceso deprecio y reembolso está en trámite. Kerendia 40 mg no está comercializado en España.

    Vericiguat is currently indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring i.v. therapy 

    Vericiguat está indicado para el tratamiento de la insuficiencia cardiaca crónica sintomática en pacientes adultos con fracción de eyección reducida que están estabilizados después de un episodio reciente de descompensación que requirió tratamiento por vía intravenosa.

    Acoramidis is currently indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

    Acoramidis está indicado para el tratamiento de la amiloidosis por transtiretina de tipo nativa o variante en pacientes adultos con miocardiopatía (ATTR-CM).

    Gene Therapy AB-1002 is an investigational gene therapy currently in phase II clinical trial. 

    AB-1002 es una terapia génica en investigación, actualmente en ensayo clínico fase II.

     

    The contents of this website are the sole property of Bayer AG​

    Last updated on April/2026

    MA-M_ACR-ES-0155-1 / April 2026

    Report a side effect:
    For adverse event reporting, please contact the Spanish system for Pharmacovigilance of human use medicines, www.notificaram.es. For other regions, please refer to your pharmacovigilance local authority. 

    Para notificar una reacción adversa, por favor, contacte con el sistema español de Farmacovigilancia de medicamentos de uso humanos, www.notificaram.es. Para otras regiones, por favor consulte su autoridad local de farmacovogilancia.

    This website is to be presented at the Annual Congress of the of the ESC HF, Saturday, 9 May - Tuesday, 12 May 2026, Barcelona - Spain. Product labels may vary from country to country, please refer to your local Prescribing Information for the proper usage and indications approved in your market.


    Finerenone in Spain is indicated in adults for the treatment of CKD (with albuminuria) associated with type 2 diabetes. The indication “Treatment of symptomatic chronic HF EF ≥40%” is approved in Spain. However, the pricing and reimbursement process is ongoing. Kerendia 40 mg is currently not marketed in Spain. 

    Finerenona en España está indicada en adultospara el tratamiento de la ERC (con albuminuria) asociada a diabetes tipo 2. La indicación “Tratamiento de la IC crónica sintomática FE ≥40%” está autorizada en España. Sin embargo, el proceso deprecio y reembolso está en trámite. Kerendia 40 mg no está comercializado en España.

    Vericiguat is currently indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring i.v. therapy 

    Vericiguat está indicado para el tratamiento de la insuficiencia cardiaca crónica sintomática en pacientes adultos con fracción de eyección reducida que están estabilizados después de un episodio reciente de descompensación que requirió tratamiento por vía intravenosa.

    Acoramidis is currently indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

    Acoramidis está indicado para el tratamiento de la amiloidosis por transtiretina de tipo nativa o variante en pacientes adultos con miocardiopatía (ATTR-CM).

    Gene Therapy AB-1002 is an investigational gene therapy currently in phase II clinical trial. 

    AB-1002 es una terapia génica en investigación, actualmente en ensayo clínico fase II.

     

    The contents of this website are the sole property of Bayer AG​

    Last updated on April/2026

    • PP-GEN-ALL-0006-1